糖尿病肾病:挑战、进展与可能性
约40%的糖尿病患者会发生糖尿病肾病,它是全球慢性肾脏病(CKD)的首要病因。尽管部分患者进展至终末期肾病(ESRD),但多数患者在需要肾脏替代治疗前死于心血管疾病和感染。现有治疗下肾病发生与进展的残余风险仍高,亟需新生物标志物、临床终点创新及靶向肾脏机制的新药研发。
要点
- 约40%糖尿病患者发生糖尿病肾病,是全球CKD首位病因。
- 多数患者在被需要肾脏替代治疗前死于心血管疾病和感染。
- 现有治疗下肾病发生与进展的残余风险仍高,亟需创新。
核心结论
- 糖尿病肾病疾病负担重,现有治疗下残余风险高,需在多方面推动创新以改善患者结局。
主要发现
- 约40%的糖尿病患者会发生糖尿病肾病,该病是全球慢性肾脏病(CKD)的首要病因。
- 尽管终末期肾病(ESRD)是糖尿病肾病最易识别的后果,但多数患者在需要肾脏替代治疗前死于心血管疾病和感染。
- 糖尿病肾病的自然病程包括肾小球高滤过、进行性白蛋白尿、肾小球滤过率(GFR)下降,最终进展至ESRD。
- 糖尿病相关的代谢改变导致肾小球肥大、肾小球硬化以及肾小管间质炎症和纤维化。
临床怎么用
- 临床应重视糖尿病肾病患者的心血管疾病和感染风险,而不仅关注肾脏替代治疗需求。
- 需推动新生物标志物应用、设计采用临床相关终点的临床试验,并研发靶向肾脏特异性机制(如肾小球高滤过、炎症和纤维化)的治疗药物。
- 应加强最佳实践在临床和社区环境中的传播与实施。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Diabetic kidney disease develops in approximately 40% of patients who are diabetic and is the leading cause of CKD worldwide. Although ESRD may be the most recognizable consequence of diabetic kidney disease, the majority of patients actually die from cardiovascular diseases and infections before needing kidney replacement therapy. The natural history of diabetic kidney disease includes glomerular hyperfiltration, progressive albuminuria, declining GFR, and ultimately, ESRD. Metabolic changes associated with diabetes lead to glomerular hypertrophy, glomerulosclerosis, and tubulointerstitial inflammation and fibrosis. Despite current therapies, there is large residual risk of diabetic kidney disease onset and progression. Therefore, widespread innovation is urgently needed to improve health outcomes for patients with diabetic kidney disease. Achieving this goal will require characterization of new biomarkers, designing clinical trials that evaluate clinically pertinent end points, and development of therapeutic agents targeting kidney-specific disease mechanisms (e.g., glomerular hyperfiltration, inflammation, and fibrosis). Additionally, greater attention to dissemination and implementation of best practices is needed in both clinical and community settings.
引用
- Alicic RZ, Rooney MT, Tuttle KR, et al. Diabetic Kidney Disease: Challenges, Progress, and Possibilities. Clin J Am Soc Nephrol. 2017. PMID: 28522654. doi:10.2215/CJN.11491116
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。